Skip to main content
Premium Trial:

Request an Annual Quote

Class Action Lawsuits Filed Against Cancer Genetics

The story has been updated to clarify language about Cancer Genetics' review of its operations.  

NEW YORK (GenomeWeb) – At least two class action lawsuits have been filed against Cancer Genetics alleging the company made false and/or misleading statements and/or failed to disclose information pertinent to investors.

One lawsuit was filed last week by Gainey McKenna & Egleston with the US District Court District of New Jersey, following Cancer Genetics' announcement of its fourth quarter financial results on April 2. At that time the company said that after a comprehensive review of its strategy and organization subsequent to the departure of its former CEO Panna Sharma, it recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivables for its fourth quarter. A significant portion of the collection issues with accounts receivables were recorded after 2015, following Cancer Genetics' $14 million acquisition of Response Genetics.

Additionally, Cancer Genetics said that on Dec. 31, 2017, its "cash position and history of losses required management to assess [its] ability to continue operating as a going concern," the law firm said in a statement. 

The lawsuit was filed on behalf of investors who acquired Cancer Genetics' stock or other securities between March 23, 2017 through April 2, 2018.

A second lawsuit was announced today by the law firm Bronstein, Gewirtz & Grossman, which also alleged that Cancer Genetics made misleading statements and failed to disclose that it "had ineffective disclosure controls and internal controls over financial reporting."

Through a spokesperson, Cancer Genetics declined to comment.

In Monday morning trade on the Nasdaq, shares of Cancer Genetics were down around 13 percent at $1.05.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more